Brian Park, PharmD

Drug Information Specialist https://www.thecardiologyadvisor.com

Brian Park, PharmD, is a Drug Information Specialist at MPR. A graduate of the Ernest Mario School of Pharmacy, Rutgers University, Brian worked as a pharmacy manager at Stop & Shop Pharmacy for 8 years. He is a certified diabetes care pharmacist.

All articles by Brian Park, PharmD

Arrhythmia

Small-Volume Presentation of Heparin Sodium Now Available in Simplist Prefilled Syringes

Brian Park, PharmD

November 12, 2019

Fresenius Kabi has announced the availability of Heparin Sodium Injection 5000 USP units per 0.5mL for anticoagulation.

Arrhythmia

Once Discontinued Antiarrhythmic Agent Will Soon Be Available Again

Brian Park, PharmD

November 7, 2019

The FDA has approved the Prior Approval Supplement for Bretylium Tosylate Injection, allowing ANI Pharmaceuticals to market the once discontinued antiarrhythmic agent.

Practice Management

New Report Identifies Causes, Potential Solutions for Drug Shortages

Brian Park, PharmD

October 31, 2019

The FDA has issued a report assembled by the inter-agency Drug Shortages Task Force to determine the root causes of drug shortages, and to offer recommendations based on the insights from stakeholders in the private and public sectors to help prevent future drug shortages.

Pulmonary Vasculature

Treprostinil Approved to Delay Disease Progression in PAH

Brian Park, PharmD

October 24, 2019

The FDA has approved the supplemental NDA for Orenitram extended-release tablets for the treatment of PAH to delay disease progression, in addition to improving exercise capacity.

General Cardiology

FDA: Stop Using Vaping Products Containing THC

Brian Park, PharmD

October 8, 2019

An updated alert from the Food and Drug Administration is warning consumers to stop using e-cigarettes or vapes.

cardiovascular disease, CVD, heart disease, MRI

Heart Failure

Canagliflozin Approved to Reduce CV Death Risk in Adults With T2D and Nephropathy

Brian Park, PharmD

October 1, 2019

The FDA has approved a new indication for Invokana to reduce the risk of end-stage renal disease, doubling of serum creatinine, CV death, and more in T2D.

ACS

Reduced Bleeding Risk With Ticagrelor Monotherapy After DAPT in High-Risk PCI Patients

Brian Park, PharmD

September 30, 2019

Ticagrelor monotherapy was associated with a lower risk of clinically relevant bleeding compared with ticagrelor plus low-dose aspirin in high-risk patients following PCI.

Dyslipidemia

Inclisiran Benefits Patients With Familial Hypercholesterolemia and ASCVD

Brian Park, PharmD

September 26, 2019

Inclisiran is a chemically synthesized small interfering RNA (siRNA) that targets proprotein convertase subtilisin-kexin type 9 (PCSK9) messenger RNA.